Episode Details
Back to EpisodesDaratumumab maintenance in newly-diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in myeloproliferative neoplasms; and novel genetic loci associated with the risk of heavy menstrual bleeding
Season 10
Published 8 months ago
Description
In this week's episode, we’ll learn more about the effects of daratumumab maintenance on minimal residual disease in patients with newly diagnosed, transplant-eligible multiple myeloma; the role of neutrophils in the pathophysiology of myeloproliferative neoplasms; and a genome-wide association study that identified novel genetic loci associated with the risk of heavy menstrual bleeding.
Featured Articles
- Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
- Defective neutrophil clearance in JAK2^V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24
- Genome-wide meta-analysis of heavy menstrual bleeding reveals 36 risk loci